Core Viewpoint - Fuhong Hanlin (02696) experienced a stock price increase of over 7%, reaching a historical high of 85.95 HKD following the release of its interim results, indicating positive market sentiment towards the company's performance and growth prospects [1] Financial Performance - The company reported a revenue of 2.82 billion RMB for the first half of the year, representing a year-on-year increase of 2.67% [1] - Gross profit reached 2.199 billion RMB, showing a year-on-year growth of 10.47% [1] - Shareholder profit attributable to the company was 390 million RMB, reflecting a slight increase of 0.99% year-on-year [1] International Expansion - The sales revenue from overseas products amounted to approximately 40.6 million RMB, with profits from these products more than doubling compared to the same period last year, driven by the company's internationalization strategy and increased sales in the U.S. market [1] - The company achieved significant milestones in its international market presence, with the approval of its product Hanshu for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in the EU in February, marking the second product approved in this market [1] - In July, the biosimilar HLX14 received a positive review opinion from the European Medicines Agency (EMA), paving the way for its market entry in Europe [1]
港股异动 | 复宏汉霖(02696)绩后涨超7%再创新高 国际化战略持续推进 上半年海外产品利润实现超2倍增长